Form 4: Director Boosts HRTX Stake with $3.8M Investment

A director of Heron Therapeutics, Inc. acquired approximately $3.8 million in common and convertible preferred stock through a private placement, increasing beneficial ownership.

Summary

• Adam Morgan, a director of Heron Therapeutics, Inc. (HRTX), acquired additional securities through Velan Capital Master Fund LP.
• The acquisition included 1,766,546 shares of common stock at $1.50 per share and 70,012 shares of Series A Convertible Preferred Stock at $15.00 per share.
• The Series A Preferred Stock is convertible into 700,120 shares of common stock at a conversion price of $1.50 per share.
• The total investment amounted to approximately $3,799,999.
• The transaction closed on August 12, 2025.
• Following the transaction, Velan Capital Master Fund LP beneficially owns 8,753,290 shares of common stock and 70,012 shares of Series A Convertible Preferred Stock.

Sentiment

Score: 7

Explanation: The significant insider investment by a director and major shareholder indicates strong confidence in the company's prospects, which is generally positive. However, the private placement at a potentially discounted price and the future dilution risk from preferred stock conversion temper the overall positive sentiment.

Positives

• Significant insider investment of approximately $3.8 million, signaling confidence in the company's future.
• The private placement provides capital to the company.
• The acquisition of convertible preferred stock offers potential for future equity upside.

Negatives

• The purchase price of $1.50 per common share (and equivalent for preferred) might be below the current market price, indicating a discount for the private placement.
• Potential for future dilution upon conversion of preferred stock, subject to shareholder approval.

Risks

• Conversion of Series A Preferred Stock is contingent on the "Stockholder Approval Proposal," introducing a dependency.
• A beneficial ownership limitation of 4.99% of outstanding common stock for Velan Master (and affiliates) after conversion, which could restrict full conversion unless increased with 61 days' notice.

Future Outlook

The Series A Convertible Preferred Stock is expected to automatically convert into common stock upon approval of the Stockholder Approval Proposal, subject to certain beneficial ownership limitations.

Management Comments

• Adam Morgan disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

This private placement by an existing director and significant shareholder is a common method for biotechnology companies like Heron Therapeutics to raise capital, especially when seeking to fund ongoing research, development, or commercialization efforts. It demonstrates continued investor confidence from within the company's leadership.

Comparison to Industry Standards

• Private placements at a discount to market price are common for biotech companies raising capital, especially those with significant R&D pipelines or commercialization needs.
• The inclusion of convertible preferred stock is a typical structure in such deals, offering investors a fixed return component (if dividends are paid) and equity upside, while providing the company with capital without immediate full dilution.
• The 4.99% beneficial ownership cap is a standard "blocker" provision often included to prevent triggering certain regulatory thresholds (e.g., Section 13(d) reporting requirements for 5% or more ownership) without prior notice or additional filings.

Related Party Transactions

• Adam Morgan, a director, is a managing member of entities related to Velan Capital Master Fund LP, which is the purchaser in this private placement.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of preferred stock, but also a signal of confidence from a major insider. The capital raise could support company operations, potentially benefiting long-term value.
• Company: Receives capital infusion to support operations and strategic initiatives.

Next Steps

• Approval of the "Stockholder Approval Proposal" for the automatic conversion of Series A Preferred Stock.
• Potential increase of the 4.99% beneficial ownership limitation by Velan Master with 61 days' notice.

Key Dates

Recommendation

While the significant insider investment signals confidence and provides capital, the potential for future dilution from the preferred stock conversion and the private placement at a potentially discounted price introduce elements of caution. Investors should hold and monitor the company's progress, particularly regarding the shareholder approval for preferred stock conversion and the utilization of the raised capital.

Keywords

Heron Therapeutics, HRTX, Adam Morgan, Velan Capital, Insider Buying, Private Placement, Convertible Preferred Stock, Biotechnology, Pharmaceuticals, SEC Form 4